免疫介导坏死性肌病的结局预测因素:一项回顾性多中心研究
该多中心回顾性研究分析了2012至2019年间经肌肉活检确诊的免疫介导坏死性肌病(IMNM)患者,评估基线临床特征和治疗变量对3个月和6个月肌力及血清肌酸激酶(CK)改善的预测作用。女性、年龄较大、初始泼尼松剂量和静脉甲泼尼龙与血清CK更大改善相关;基线中重度疾病患者中,早期静脉注射免疫球蛋白(IVIG)与6个月时髋屈肌力量更大改善相关。
要点
- 女性、年龄较大、初始泼尼松剂量及静脉甲泼尼龙与血清CK更大改善相关。
- 基线中重度IMNM患者中,早期IVIG与6个月时髋屈肌力量更大改善相关。
- 早期IVIG与短期随访中临床改善相关。
核心结论
- 早期IVIG与IMNM短期随访中的临床改善相关。
- 女性、年龄较大、初始口服泼尼松剂量及初始使用静脉甲泼尼龙与更好的生化改善相关。
研究设计与样本
- 多中心回顾性研究,肌肉活检取自John Hunter医院和皇家阿德莱德医院2012至2019年的标本,在南澳大利亚病理学实验室单一实验室复核。
- 识别所有具有IMNM组织学特征的活检,记录人口学、临床信息、肌炎特异性抗体状态及基线、3个月和6个月时的肌力、血清CK和治疗方案。
- 主要结局指标为3个月和6个月时的肌力和血清CK,采用贝叶斯框架下的混合效应回归模型(R统计软件包)进行分析。
主要发现
- 女性、年龄较大、初始泼尼松剂量和静脉甲泼尼龙与血清CK更大改善相关。
- 基线中重度疾病患者中,早期IVIG与6个月时髋屈肌力量更大改善相关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Evidence-based treatment protocols are currently lacking for immune-mediated necrotizing myopathy (IMNM). In this multicentre retrospective study, we examined baseline clinical characteristics and treatment variables that may predict short-term outcomes of patients with IMNM. METHODS: Muscle biopsies from the John Hunter Hospital and the Royal Adelaide Hospital obtained between 2012 and 2019 were reviewed at a single laboratory at South Australia Pathology. All biopsies with histological features of IMNM were identified. Demographics of study subjects, clinical information and myositis-specific antibody status were recorded along with muscle strength, serum creatine kinase (CK) and treatment regimens at baseline and 3 and 6 months. Primary outcome measures were muscle strength and serum CK at 3 and 6 months. Mixed-effects regression models in a Bayesian framework were performed using the R statistical package. RESULTS: Female sex, older age, initial prednisone dose and i.v. methylprednisolone were associated with greater improvement in serum CK. In patients with moderate-severe disease at baseline, early IVIG was associated with greater improvement in hip flexor strength at 6 months. CONCLUSION: Early IVIG was associated with clinical improvement in the short-term follow-up in IMNM. Female sex, older age, initial oral prednisone dose and initial use of i.v. methylprednisolone were associated with better biochemical improvement.
引用
- Wang JX, Wilkinson M, Oldmeadow C, et al. Outcome predictors of immune-mediated necrotizing myopathy-a retrospective, multicentre study. Rheumatology (Oxford). 2022. PMID: 35022671. doi:10.1093/rheumatology/keac014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。